Recently, with the development of targeted therapies, imatinib mesylate (also known as Gleevec), a selective inhibitor against mutant forms of type III tyrosine kinases, such as KIT, PDGFRA and ABL, has been used as a standard first-line treatment for irresectable and metastasized GIST patients or adjuvant treatment for advanced GIST patients and has showed dramatically altered in the respect of 5 year survival and recurrence rate11, 12, 13, 14. This evidence concerns the gene KIT and gastrointestinal stromal tumor.